Agenus Inc. (AGEN): Price and Financial Metrics
GET POWR RATINGS... FREE!
AGEN POWR Grades
- AGEN scores best on the Value dimension, with a Value rank ahead of 60.17% of US stocks.
- AGEN's strongest trending metric is Growth; it's been moving down over the last 178 days.
- AGEN's current lowest rank is in the Stability metric (where it is better than 2.71% of US stocks).
AGEN Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for AGEN is -4.41 -- better than just 3.1% of US stocks.
- AGEN's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 99.3% of US stocks.
- Revenue growth over the past 12 months for AGENUS INC comes in at -70.69%, a number that bests merely 2.46% of the US stocks we're tracking.
- Stocks that are quantitatively similar to AGEN, based on their financial statements, market capitalization, and price volatility, are STX, CLNN, INFI, XCUR, and WVE.
- AGEN's SEC filings can be seen here. And to visit AGENUS INC's official web site, go to agenusbio.com.
AGEN Valuation Summary
- AGEN's EV/EBIT ratio is -5.1; this is 158.62% lower than that of the median Healthcare stock.
- AGEN's price/sales ratio has moved down 80.7 over the prior 243 months.
Below are key valuation metrics over time for AGEN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| AGEN | 2022-12-02 | 10.1 | -44.4 | -4.2 | -5.1 |
| AGEN | 2022-12-01 | 9.0 | -39.5 | -3.7 | -4.4 |
| AGEN | 2022-11-30 | 9.2 | -40.4 | -3.8 | -4.5 |
| AGEN | 2022-11-29 | 8.9 | -39.3 | -3.7 | -4.4 |
| AGEN | 2022-11-28 | 9.1 | -40.1 | -3.8 | -4.5 |
| AGEN | 2022-11-25 | 9.5 | -42.0 | -4.0 | -4.7 |
AGEN Growth Metrics
- The 5 year net cashflow from operations growth rate now stands at -62.3%.
- Its 4 year revenue growth rate is now at 277.8%.
- The 4 year net cashflow from operations growth rate now stands at -62.3%.
The table below shows AGEN's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 89.9 | -150.962 | -214.704 |
| 2022-06-30 | 320.082 | 12.602 | 18.07 |
| 2022-03-31 | 309.886 | 0.498 | -18.786 |
| 2021-12-31 | 295.665 | 10.145 | -24.137 |
| 2021-09-30 | 306.667 | -2.518 | 3.767 |
| 2021-06-30 | 68.545 | -165.517 | -225.937 |
AGEN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- AGEN has a Quality Grade of C, ranking ahead of 55.26% of graded US stocks.
- AGEN's asset turnover comes in at 0.324 -- ranking 139th of 681 Pharmaceutical Products stocks.
- COCP, MTEM, and LGND are the stocks whose asset turnover ratios are most correlated with AGEN.
The table below shows AGEN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.324 | 0.949 | 8.194 |
| 2021-03-31 | 0.404 | 0.959 | 5.948 |
| 2020-12-31 | 0.449 | 0.973 | 3.708 |
| 2020-09-30 | 0.504 | 0.983 | 2.706 |
| 2020-06-30 | 0.555 | 0.993 | 2.612 |
| 2020-03-30 | 0.476 | 1.000 | 2.580 |
AGEN Price Target
For more insight on analysts targets of AGEN, see our AGEN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $10.00 | Average Broker Recommendation | 1.17 (Strong Buy) |
AGEN Stock Price Chart Interactive Chart >
AGEN Price/Volume Stats
| Current price | $2.75 | 52-week high | $3.62 |
| Prev. close | $2.97 | 52-week low | $1.25 |
| Day low | $2.73 | Volume | 1,731,121 |
| Day high | $2.95 | Avg. volume | 4,575,513 |
| 50-day MA | $2.58 | Dividend yield | N/A |
| 200-day MA | $2.40 | Market Cap | 838.23M |
Agenus Inc. (AGEN) Company Bio
Agenus Inc. engages in discovering and developing innovative treatments for patients with cancer and other diseases. The company was founded in 1994 and is based in Lexington, Massachusetts.
Latest AGEN News From Around the Web
Below are the latest news stories about AGENUS INC that investors may wish to consider to help them evaluate AGEN as an investment opportunity.
Agenus Data at CTOS 2022 Highlight Durable Clinical Responses of Botensilimab / Balstilimab Combination in Advanced SarcomaOverall response rate (ORR) of 46% and disease control rate (DCR) of 69% in heavily pre-treated patients who have received a median of 3 prior lines of therapyPatient responses include sarcoma subtypes that historically do not respond to immunotherapy, including responses in 3 of 4 patients with visceral angiosarcoma67% of patient responses have exceeded one year and remain ongoing at data cut-offPhase 2 trial of botensilimab/balstilimab in sarcomas planned for 2023 LEXINGTON, Mass., Nov. 17, 20 |
Agenus to Participate at 5th Annual Evercore ISI HealthCONx ConferenceLEXINGTON, Mass., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and infectious disease, today announced that Dr. Garo Armen, Chairman and CEO of Agenus, and Dr. Steven O’Day, Chief Medical Officer, will participate in a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Wednesday, November 30th at 12:35pm ET. The Conference will be held virtually from November 29th – December 1st, during which |
Analysts’ Top Healthcare Picks: Airsculpt Technologies, Inc. (AIRS), Agenus (AGEN)There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Airsculpt Technologies, Inc. (AIRS – Research Report) and Agenus (AGEN – Research Report) with bullish sentiments. Airsculpt Technologies, Inc. (AIRS) SVB Securities analyst Whit Mayo maintained a Buy rating on Airsculpt Technologies, Inc. today and set a price target of $8.00. The company's shares closed last Friday at $3.28, close to its 52-week low of $3.23. According to TipRanks. |
Agenus Data at SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant CancersOverall response rates ranged from 22% in microsatellite stable colorectal cancer (MSS-CRC) to 60% in PD-(L)1 refractory non-small cell lung cancer (NSCLC)Initiated Phase 2 ACTIVATE trials of botensilimab in advanced MSS-CRC and advanced melanoma; pancreatic cancer to follow before year-end LEXINGTON, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Agenus (Nasdaq: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and infectious disease, announced expanded data from the Company’s |
Agenus Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS LagsAgenus ( NASDAQ:AGEN ) Third Quarter 2022 Results Key Financial Results Revenue: US$22.8m (down 91% from 3Q 2021). Net... |
AGEN Price Returns
| 1-mo | 12.70% |
| 3-mo | 13.64% |
| 6-mo | 61.76% |
| 1-year | -5.82% |
| 3-year | -29.67% |
| 5-year | -25.47% |
| YTD | -14.60% |
| 2021 | 1.26% |
| 2020 | -21.87% |
| 2019 | 71.01% |
| 2018 | -26.99% |
| 2017 | -20.87% |
Continue Researching AGEN
Here are a few links from around the web to help you further your research on Agenus Inc's stock as an investment opportunity:Agenus Inc (AGEN) Stock Price | Nasdaq
Agenus Inc (AGEN) Stock Quote, History and News - Yahoo Finance
Agenus Inc (AGEN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...